share_log

HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $10 Price Target

Benzinga ·  Apr 23 18:28

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $10 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment